PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021 revenues are approximately US$40 million. […]
Menu ≡ ╳ 
